Sestrin 2 confers primary resistance to sorafenib by simultaneously activating AKT and AMPK in hepatocellular carcinoma

Sestrin 2 confers primary resistance to sorafenib by simultaneously activating AKT and AMPK in hepatocellular carcinoma

Abstract Hepatocellular carcinoma (HCC) is the malignancy derived from normal hepatocytes with increasing incidence and extremely poor prognosis worldwide. The only approved first‐line systematic treatment agent for HCC, sorafenib, is capable to effectively improve advanced HCC patients’ survival. H...

Full description

Bibliographic Details
Main Authors: Jimin Dai, Qichao Huang, Kunwei Niu, Bo Wang, Yijie Li, Chen Dai, Zhinan Chen, Kaishan Tao, Jingyao Dai
Format: Article
Language:English
Published: Wiley 2018-11-01
Series:Cancer Medicine
Subjects:
AKT
AMPK
hepatocellular carcinoma
primary resistance
Sestrin2
sorafenib
Online Access:https://doi.org/10.1002/cam4.1826

Internet

https://doi.org/10.1002/cam4.1826

Similar Items